Literature DB >> 10590503

New concepts in atrial defibrillation.

G M Ayers1.   

Abstract

External cardioversion of AF is an established and accepted method for termination of individual episodes of AF. Recent advances have taken place in the area of non-pharmacologic management of AF, and despite its long history and well established technique, defibrillation has not been spared from these advances. The success of low-energy internal atrial defibrillation for the termination of both chronic and acute onset atrial fibrillation has resulted in the development of implantable defibrillators that treat this arrhythmia. Many of the advances have come about as a result of the use of defibrillation in implanted devices for recurrent AF due to the substantial efforts in an attempt to make this form of restoration of sinus rhythm more efficacious and tolerable to the patient. Additionally, the use of other non-pharmacologic control of atrial fibrillation has also been recently explored, namely the use of ablation and atrial pacing. The use of these other non-pharmacologic therapies are likely to both reduce the recurrence rate, as well as enhance the efficacy of defibrillation. However, defibrillation is likely to still be needed to terminate atrial fibrillation for persistent episodes, and its combination with these other therapies is likely synergistic. Electrical therapy to restore sinus rhythm for persistent episodes of atrial fibrillation is likely to be perceived by the patient. Therefore, the concept of patient controlled therapy from implanted devices to treat atrial fibrillation has shown promising results and will likely be a requirement of such devices in the future. Major advances in defibrillation therapy for atrial fibrillation have been made and have resulted in the development of implantable atrial defibrillators. Despite these advances in defibrillation and other therapies for atrial fibrillation, it is likely that combined pharmacologic and non-pharmacologic therapies for atrial fibrillation will prevail over the individual entities themselves. Future study is needed to determine the best therapy or combination of therapies for individual patients with atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10590503     DOI: 10.1023/a:1009863522664

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  19 in total

1.  New method for terminating cardiac arrhythmias. Use of synchronized capacitor discharge.

Authors:  B LOWN; R AMARASINGHAM; J NEUMAN
Journal:  JAMA       Date:  1962-11-03       Impact factor: 56.272

2.  Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation.

Authors:  C Schmitt; E Alt; A Plewan; R Ammer; M Leibig; M Karch; A Schömig
Journal:  J Am Coll Cardiol       Date:  1996-10       Impact factor: 24.094

3.  Efficacy and tolerability in fully conscious patients of transvenous low-energy internal atrial cardioversion for atrial fibrillation.

Authors:  G Boriani; M Biffi; G Bronzetti; G M Ayers; R Zannoli; A Branzi; A Capucci; B Magnani
Journal:  Am J Cardiol       Date:  1998-01-15       Impact factor: 2.778

4.  An implantable atrial defibrillator. An impossible dream?

Authors:  S Levy; J Camm
Journal:  Circulation       Date:  1993-05       Impact factor: 29.690

5.  Atrial fibrillation detection and R-wave synchronization by Metrix implantable atrial defibrillator: implications for long-term efficacy and safety. The Metrix Investigators.

Authors:  H F Tse; C P Lau; J S Sra; H J Crijns; N Edvardsson; S Kacet; D G Wyse
Journal:  Circulation       Date:  1999-03-23       Impact factor: 29.690

6.  Immediate reinitiation of atrial fibrillation following internal atrial defibrillation.

Authors:  C Timmermans; L M Rodriguez; J L Smeets; H J Wellens
Journal:  J Cardiovasc Electrophysiol       Date:  1998-02

7.  Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation.

Authors:  S Lévy; P Ricard; C P Lau; N S Lok; A J Camm; F D Murgatroyd; L J Jordaens; L J Kappenberger; P Brugada; K L Ripley
Journal:  J Am Coll Cardiol       Date:  1997-03-15       Impact factor: 24.094

8.  Clinical shock tolerability and effect of different right atrial electrode locations on efficacy of low energy human transvenous atrial defibrillation using an implantable lead system.

Authors:  N S Lok; C P Lau; H F Tse; G M Ayers
Journal:  J Am Coll Cardiol       Date:  1997-11-01       Impact factor: 24.094

9.  Marked reduction in internal atrial defibrillation thresholds with dual-current pathways and sequential shocks in humans.

Authors:  R A Cooper; V J Plumb; A E Epstein; G N Kay; R E Ideker
Journal:  Circulation       Date:  1998-06-30       Impact factor: 29.690

10.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats.

Authors:  M C Wijffels; C J Kirchhof; R Dorland; M A Allessie
Journal:  Circulation       Date:  1995-10-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.